

AMENDMENT TO THE CLAIMS:

1-28 (Cancelled)

29. (Currently amended): A method for ameliorating the effects of inflammation in a subject which comprises administering one or more antibodies selected from the group consisting of:

- (i) an antibody specific for M-CSF,
- (ii) an antibody specific for GM-CSF, and
- (iii) a combination of (i) and (ii),

for a time and in an amount to inhibit or otherwise antagonize the effects of M-CSF or GM-CSF on cells of the monocyte/macrophage lineage.

30. (Currently Amended): The method of Claim 29, wherein inhibiting or otherwise antagonizing the effects of M-CSF, GM-CSF or both on cells of the monocyte/macrophage lineage comprises reducing the level of proliferation, activation, growth and/or survival of cells of the monocyte/macrophage lineage.

31. (Currently Amended): The method of Claim 29 or 30, wherein said antibodies antagonize the effects of M-CSF, GM-CSF or both ~~of the monocyte/macrophage lineage~~.

32. (Previously Presented): The method of Claim 29 or 30, wherein the antibodies are identified through natural product screening or screening of a chemical library.

33. (Previously Presented): The method of Claim 31, wherein the antibodies are internalized by the monocyte/macrophage cells.

34. (Previously Presented): The method of Claim 29 or 30 which further comprises administering an antibody which antagonizes the effects of u-PA.

35. (Cancelled).